Archive for September 2023
Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia.
Goulooze S.C., Yang S, Mesic E, Beerahee M, Post T.M, Mahar K.M. Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]
Read MoreInnovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration based dosing, applied to a population dose hemoglobin model for Jesduvroq (daprodustat).
Goulooze S.C., Noort van M., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M. Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration based dosing, applied to a population dose hemoglobin model for Jesduvroq (daprodustat). PAGE 2023 [Link to publication]
Read MoreTwo New User-Friendly Approaches to Assess Pharmacometric Model Identifiability.
Noort van M., DeJongh J. Two New User-Friendly Approaches to Assess Pharmacometric Model Identifiability. PAGE 2023 [Link to publication]
Read MoreLinking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight.
Bosch R., Snelder N. Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight. PAGE 2023 [Link to publication]
Read MorePopulation PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients.
Marostica E., Ahsman M., Van Bragt T., Noukens J., T’joen C., Ulrichts P., Vis P., Rossenu S., Steeg van T. Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients. PAGE 2023 [Link to publication]
Read MoreDevelopment of a joint tumor size (TS)−overall survival (OS) modeling and simulation (M&S) framework supporting oncology development decision making.
Struemper H., Rathi C., Muliaditan M., Goulooze S.C., Mantero A., Post T.M., Visser S.A.G. Development of a joint tumor size (TS)−overall survival (OS) modeling and simulation (M&S) framework supporting oncology development decision making. PAGE 2023 [Link to publication]
Read MoreConditional Overall Survival (OS) Simulations With a Joint Tumor Size (TS)-OS Model to Support Oncology Development Decision Making.
Goulooze S.C., Muliaditan M., Mantero A., Visser S.A.G., Post T.M., Rathi C., Struemper H. Conditional Overall Survival (OS) Simulations With a Joint Tumor Size (TS)-OS Model to Support Oncology Development Decision Making. PAGE 2023. [Link to publication]
Read MoreFrom glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies.
Noort van M., Ruppert M., Goulooze S.C., Berg van den P., Snelder N., Heerspink H.J., Garmann D., Lippert J., Heinig R., Brinker M., Eissing T. From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies. PAGE 2023 [Link to publication]
Read MorePopulation dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia.
Noort van M., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S. Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]
Read MoreBuilding an adaptive dose simulation framework to aid dose and schedule selection.
Richard Hooijmaijers R., Parasrampuria R., Marostica E., Ferron-Brady G., Post T.M., Visser S.A.G. Building an adaptive dose simulation framework to aid dose and schedule selection. CPT: Pharmacometirics & Systems Pharmacology, 2023. [Link to publication].
Read More